Adicet Bio Inc
NASDAQ:ACET

Watchlist Manager
Adicet Bio Inc Logo
Adicet Bio Inc
NASDAQ:ACET
Watchlist
Price: 8.15 USD -7.6% Market Closed
Market Cap: 78.1m USD

Adicet Bio Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Adicet Bio Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Adicet Bio Inc
NASDAQ:ACET
Free Cash Flow
-$100.3m
CAGR 3-Years
-27%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

Adicet Bio Inc
Glance View

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2018-01-26. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its lead product candidate, ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is under Phase I study for the treatment of Non-Hodgkin's Lymphoma. Its pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15, for the treatment of solid tumors. In addition, it is engaged in discovery and preclinical stage activities of its pipeline of product candidates for both hematological malignancies and solid tumors.

ACET Intrinsic Value
Not Available

See Also

What is Adicet Bio Inc's Free Cash Flow?
Free Cash Flow
-100.1m USD

Based on the financial report for Jun 30, 2025, Adicet Bio Inc's Free Cash Flow amounts to -100.1m USD.

What is Adicet Bio Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-8%

Over the last year, the Free Cash Flow growth was -8%. The average annual Free Cash Flow growth rates for Adicet Bio Inc have been -27% over the past three years , -8% over the past five years .

Back to Top